PBAC Public Summary Document

Page last updated: 18 November 2022

The Public Summary Documents for the Review of the base-case discount rate in the Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines from the July 2022 PBAC meeting and the section 19A medicines (dulaglutide and semaglutide) that were considered out-of-session between July 2022 and November 2022 by the PBAC are now available.